Epidermal growth factor receptors (EGFR) in human ovarian cancer.
Epidermal growth factor receptor can be used as a biological marker in tumours. We examined 199 samples from 150 patients with ovarian cancer first by using a single point screen, then by full Scatchard analysis, over a concentration range between 0.086-16.6 nM. Taking as positive those samples which showed a 20% difference between total binding and non specific binding, the EGFR was present in 39.7% of samples ranging from 36.4% in those tumours which were classified as being mucinous to 47.7% in the undifferentiated group. Thirty-six samples had a low affinity component (Kd greater than 1 nM), 27 had a high affinity component (Kd less than 1 nM) and 16 had both high and low affinity components to the EGFR. There was no statistical difference between degree of differentiation of the tumour and the presence of the EGFR nor between stage of the disease and EGFR presence.
Department of Biochemistry, Glasgow University, UK.
O J
OJ
Owens
C
C
Stewart
I
I
Brown
R E
RE
Leake
D066246:ErbB Receptors / Q000502:physiology*; D005260:Female; D006801:Humans; D007700:Kinetics; D008566:Membranes / Q000378:metabolism; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000648:ultrastructure*; D010920:Placenta / Q000378:metabolism / Q000648:ultrastructure
D066246:ErbB Receptors